Option chain shows key data for Lennar's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lennar.

Lennar (NYSE:LEN) Stock, Option Chain

Lennar

NADSAQ:INTC

nasdaq:aapl

NASDAQ:AMAT

NASDAQ:APOL

NASDAQ:INTC

NASDAQ:NVDA

NASDAQ:RIMM

nasdaq:shld

NYSE:AA

NYSE:AMD

NYSE:AXP

nyse:bby

NYSE:FCX

nyse:gm

NYSE:HAL

NYSE:HD

NYSE:HPQ

NYSE:JPM

NYSE:LEN

nyse:m

NYSE:MBI

NYSE:RIG

NYSE:RIO

NYSE:SVU

nyse:t

nyse:tif

NYSE:TLB

nyse:vz

Soaring Crude Nudges Markets Higher

Propped Up By Energy Stocks, Markets Cling to Green

Energy Stocks Power Mini Rally on Wall Street

<p>Citigroup  analyst Daniel Grosslight   maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Buy and lowers the price target from $713 to $677.</p>


News

Price Target

Analyst Ratings

Citigroup Maintains Buy on McKesson, Lowers Price Target to $677

<p>In the last three months, 11 analysts have published ratings on Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $90.18, a high estimate of $110.00, and a low estimate of $76.00. Experiencing a 2.94% decline, the current average is now lower than the previous average price target of $92.91. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535677_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Lam Research by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Stacy Rasgon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$76.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lam Research. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lam Research compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lam Research's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lam Research's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LRCX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lam Research analyst ratings.</strong></a></p>
<h2>Delving into Lam Research's Background</h2>
<p>Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.</p>
<h3>Lam Research: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Lam Research displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.7%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Lam Research's net margin excels beyond industry benchmarks, reaching <strong>26.79%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Lam Research's ROE excels beyond industry benchmarks, reaching <strong>13.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lam Research's ROA excels beyond industry benchmarks, reaching <strong>5.83%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.59</strong>, Lam Research faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LRCX

Expert Outlook: Lam Research Through The Eyes Of 11 Analysts

<p>In the latest quarter, 10 analysts provided ratings for Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Olin, presenting an average target of $47.0, a high estimate of $56.00, and a low estimate of $41.00. Highlighting a 8.38% decrease, the current average has fallen from the previous average price target of $51.30. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535660_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Olin by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Bhavesh Lodaya</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Olin. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Olin compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Olin's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Olin's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OLN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Olin analyst ratings.</strong></a></p>
<h2>Discovering Olin: A Closer Look</h2>
<p>Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.</p>
<h3>Understanding the Numbers: Olin's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Challenges:</strong> Olin's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-4.9%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Olin's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.57%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-1.19%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Olin's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.33%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Olin's debt-to-equity ratio surpasses industry norms, standing at <strong>1.56</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 10 Analyst Projections For Olin

<p>Ratings for Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $30.71, a high estimate of $40.00, and a low estimate of $26.00. Highlighting a 19.18% decrease, the current average has fallen from the previous average price target of $38.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535653_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Option Care Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Option Care Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Option Care Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Option Care Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Option Care Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OPCH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Option Care Health analyst ratings.</strong></a></p>
<h2>Delving into Option Care Health's Background</h2>
<p>Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.</p>
<h3>Unraveling the Financial Story of Option Care Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Option Care Health showcased positive performance, achieving a revenue growth rate of <strong>16.97%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Option Care Health's net margin excels beyond industry benchmarks, reaching <strong>4.21%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Option Care Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.8%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.59%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Option Care Health's debt-to-equity ratio is below the industry average at <strong>0.86</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OPCH

Assessing Option Care Health: Insights From 7 Financial Analysts

<p>Ratings for Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Targa Resources, presenting an average target of $201.67, a high estimate of $246.00, and a low estimate of $171.00. Surpassing the previous average price target of $172.62, the current average has increased by 16.83%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535645_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Targa Resources among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holly Stewart</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$218.00</td>
<td>-</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$223.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$204.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shneur Gershuni</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$246.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$199.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Sunil Sibal</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$174.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Targa Resources. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Targa Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Targa Resources's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRGP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Targa Resources analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Targa Resources</h2>
<p>Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.</p>
<h3>Targa Resources: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Targa Resources's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-1.15%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Targa Resources's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.98%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Targa Resources's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.25%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.78%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Targa Resources's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>5.57</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TRGP

15 Analysts Assess Targa Resources: What You Need To Know

<p>In the latest quarter, 5 analysts provided ratings for Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $116.6, along with a high estimate of $130.00 and a low estimate of $105.00. Observing a 8.21% increase, the current average has risen from the previous average price target of $107.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535635_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Stifel Financial by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Cho</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stifel Financial. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stifel Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Stifel Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Stifel Financial's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Stifel Financial analyst ratings.</strong></a></p>
<h2>About Stifel Financial</h2>
<p>Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.</p>
<h3>Stifel Financial's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Stifel Financial's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>17.25%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Stifel Financial's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>12.35%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Stifel Financial's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Stifel Financial's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.39%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Stifel Financial's debt-to-equity ratio is below the industry average at <strong>0.32</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Stifel Financial Stock

<p>Across the recent three months, 10 analysts have shared their insights on Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $235.8, a high estimate of $259.00, and a low estimate of $212.00. Surpassing the previous average price target of $228.11, the current average has increased by 3.37%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535624_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Marsh &amp; McLennan. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$214.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$242.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$246.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$228.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$259.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$212.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$242.00</td>
<td>$232.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Marsh &amp; McLennan. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Marsh &amp; McLennan compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Marsh &amp; McLennan's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Marsh &amp; McLennan's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Marsh &amp; McLennan analyst ratings.</strong></a></p>
<h2>Get to Know Marsh &amp; McLennan Better</h2>
<p>Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.</p>
<h3>Marsh &amp; McLennan: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Marsh &amp; McLennan's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>5.85%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Marsh &amp; McLennan's net margin excels beyond industry benchmarks, reaching <strong>13.11%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Marsh &amp; McLennan's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.52%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Marsh &amp; McLennan's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.52%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.08</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 10 Analysts Discuss Marsh & McLennan Stock

<p><strong>Casey's General Stores's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NYSE">CASY</a>) short percent of float has fallen 20.16% since its last report. The company recently reported that it has <strong>744 thousand shares sold short</strong>, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.68 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Casey's General Stores Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535622_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Casey's General Stores has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Casey's General Stores's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Casey's General Stores's peer group average for short interest as a percentage of float is 9.49%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

CASY

Peering Into Casey's General Stores's Recent Short Interest

<p>Citigroup  analyst Daniel Grosslight   maintains MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) with a Neutral and raises the price target from $10 to $12.5.</p>


MPLN

Citigroup Maintains Neutral on MultiPlan, Raises Price Target to $12.5

<p><strong>Plug Power's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NYSE">PLUG</a>) short percent of float has risen 8.93% since its last report. The company recently reported that it has <strong>212.69 million shares sold short</strong>, which is 23.43% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.75 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Plug Power Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535617_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Plug Power has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Plug Power's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Plug Power's peer group average for short interest as a percentage of float is 6.00%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


PLUG

How Is The Market Feeling About Plug Power?

<p><strong>Serve Robotics's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NYSE">SERV</a>) short percent of float has fallen 37.07% since its last report. The company recently reported that it has <strong>2.49 million shares sold short</strong>, which is 8.32% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Serve Robotics Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736535612_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Serve Robotics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Serve Robotics's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Serve Robotics's peer group average for short interest as a percentage of float is 6.18%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


SERV

How Is The Market Feeling About Serve Robotics?

<p><strong>Truist</strong> analyst William Stein attended <a target="_blank" href="https://www.benzinga.com/topic/ces" rel="noreferrer noopener">CES 2025 this</a> past week and hosted several meetings with high-profile companies in the semiconductor sector.</p>
<p>The over-arching theme is that spending on AI infrastructure is firm, which benefits <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as it penetrates the $35 billion client compute market, challenging <strong>Intel Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and <strong>Advanced Micro Devices, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).</p>
<p>Demand for diversified end market semiconductors is mixed to weak, with <strong>ON Semiconductor Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) sounding particularly weak,<a href="https://www.benzinga.com/quote/on/analyst-ratings"> prompting an analyst downgrade</a>. Additionally, Stein increased his <strong>Analog Devices, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) price target.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/01/42843417/nvidia-highlights-ai-chips-powering-pubg-robotics-chatgpt-moment-automotive-expansion-and-more-at-ces-event" rel="noreferrer noopener">Nvidia Highlights AI Chips Powering PUBG, Robotics &#8216;ChatGPT Moment,&#8217; Automotive Expansion And More At CES Event</a></strong></p>
<p>Stein noted Nvidia as the AI company, a sustainable leader in massively parallel and heterogeneous compute chips, software, and, lately, services to enable AI &amp; related applications. Nvidia&#8217;s leadership is steered more by its culture of innovation, an ecosystem of incumbency, and substantial investment in software, services, and base AI models, making its chips a default choice for most engineers building AI systems.</p>
<p>The analyst expects Nvidia&#8217;s superior gaming and server acceleration positioning and AI to support structural fundamental growth and stock outperformance. Stein noted that Analog Devices is capitalizing on sound organic investments and creating a better future with M&amp;A, including accelerating sales growth and improving expense efficiencies.</p>
<p>After a series of stumbles, Intel lost its leadership positions in semiconductor manufacturing process technology to <strong>Taiwan Semiconductor Manufacturing Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and CPU performance to AMD. </p>
<p>The company recently established a clear goal to regain process and product leadership. Currently, and over the next few years, the company&#8217;s competitive position, margins, and cash flows have subsided.</p>
<p>On Semiconductor is in the middle to late innings of a significant transformation. The changes are rooted in shifting to an &#8220;IP-first&#8221; strategy from a &#8220;manufacturing-first&#8221; strategy. Unfortunately, the company is experiencing a substantial shortfall in demand that mutes Stein&#8217;s optimism in the near to medium term.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42872581/microns-7-billion-bet-on-ai-driven-memory-singapore-facility-set-to-boost-innovation-and-jobs" target="_blank" rel="noreferrer noopener">Micron&#8217;s $7 Billion Bet on AI-Driven Memory In Singapore Facility Set to Boost Innovation</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Analyst Color

Downgrades

INTC

NVDA

Nvidia's AI Leadership Shines While ON Semiconductor Faces Demand Slump: Analyst

<p>Citigroup  analyst Daniel Grosslight   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $31 to $35.</p>


Citigroup Maintains Buy on Phreesia, Raises Price Target to $35

<p>Citigroup  analyst Christopher Allen   maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and lowers the price target from $85 to $80.</p>


SCHW

Citigroup Maintains Neutral on Charles Schwab, Lowers Price Target to $80

Rumors

OKUR

Watching OnKure Therapeutics; Shares See Volume As Traders Circulate Stock Moving In Sympathy With Eli Lilly's Acquisition Talks To Buy Scorpion Therapeutics; Co Developing A Mutant-Selective PI3Kα Inhibitor

RLAY

Relay Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -13.5%

<p>JPMorgan shifted gears on <a href="https://www.benzinga.com/topic/mobility">air mobility stocks</a> <strong>Archer Aviation Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and <strong>Joby Aviation Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), downgrading them despite strong sector enthusiasm.</p>
<p>Analyst <strong>Bill Peterson</strong> adjusted Archer Aviation stock to a Neutral rating and Joby Aviation stock to Underweight, noting their significant market gains surged past what fundamentals justify.</p>
<h1 class="wp-block-heading"><strong>Market Enthusiasm Outpaces Fundamentals</strong></h1>
<p>Peterson highlighted that Archer and Joby have outperformed the Clean Tech sector, gaining 145% and 86%, respectively, over the past six months. This rise correlates with speculative inflows and market movements aligned with <strong>Tesla Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and <strong>Rocket Lab USA Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>). &#8220;These companies are trading as if regulatory hurdles have already been cleared,&#8221; Peterson stated, warning that elevated valuations could retreat as regulatory challenges persist.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">Tesla Launches Refreshed Model Y In China Amid Rising Competition</a></strong></p>
<h1 class="wp-block-heading"><strong>Certification Challenges Continue</strong></h1>
<p>Despite potential regulatory possibly easing under the upcoming <strong>Trump</strong> administration, ongoing safety testing and certification remain hurdles. Peterson sees <a href="https://www.benzinga.com/24/12/42464770/whats-going-on-with-archer-aviation-stock-today">Archer&#8217;s partnership with defense tech company Anduril</a> as promising but believes its immediate valuation upside is capped.</p>
<p>He assigned a $9 price target, reflecting incremental earnings potential from its defense ventures.</p>
<p>Similarly, while Joby&#8217;s leadership in for-credit testing and partnerships,<a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs"> such as with </a><strong><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs">Toyota Motor Corp</a> </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), indicate future growth, Peterson remains cautious.</p>
<p>The raised price target of $6 still implies downside risk due to certification uncertainties and market volatility.</p>
<h1 class="wp-block-heading"><strong>Balancing Growth Potential, Risks</strong></h1>
<p>Peterson anticipates potential capital raises to fund commercialization efforts for both companies. </p>
<p>&#8220;Investors must tread carefully,&#8221; he warned, suggesting that high short interest could lead to rapid price declines despite operational progress. </p>
<p>As Archer and Joby push toward commercialization, the analyst sees significant long-term potential but remains wary of near-term risks tied to market enthusiasm outpacing operational milestones.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/tech/25/01/42909739/onvo-l60-delivers-big-for-nio-over-20000-vehicles-sold-in-first-100-days">Onvo L60 Delivers Big For Nio: Over 20,000 Vehicles Sold In First 100 Days</a></strong></li>
</ul>
<p><em>Photo: Courtesy Joby Aviation</em></p>


Long Ideas

Tech

ACHR

JOBY

RKLB

TSLA

eVTOL Market Soars Too High? Analyst Gives Archer, Joby Downgrades

Relay Therapeutics Shares Resume Trade

CHSN

Chanson International Shares Resume Trade

<p><a href="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2" title="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2">https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2</a></p>


"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times

RBC Capital

Citigroup

Goldman Sachs

Keefe, Bruyette & Woods

Comments

Lennar

Lennar (NYSE:LEN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga